A case report with prolonged cholinesterase inhibition and improvement after pralidoxime therapy

Jefferey L Burgess, Jeffrey N. Bernstein, Katherine Hurlbut

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

AIdicarb is the most potent of the commercially available carbamate pesticides and is an unusual source of acute human poisonings. We present the case of a 43-year-old man exposed to aldicarb who developed severe cholinergic symptoms and progressive weakness requiring intubation for 5 days. Both his red blood cell cholinesterase and plasma pseudocholinesterase levels were depressed for a minimum of 44 hours. He demonstrated neuromuscular improvement concurrent with pralidoxime administration. The pertinent medical literature on aldicarb poisoning is reviewed.

Original languageEnglish (US)
Pages (from-to)221-224
Number of pages4
JournalArchives of Internal Medicine
Volume154
Issue number2
StatePublished - Jan 24 1994

Fingerprint

Aldicarb
Cholinesterases
Poisoning
Pseudocholinesterase
Carbamates
Pesticides
Intubation
Cholinergic Agents
Erythrocytes
Therapeutics
pralidoxime

ASJC Scopus subject areas

  • Internal Medicine

Cite this

A case report with prolonged cholinesterase inhibition and improvement after pralidoxime therapy. / Burgess, Jefferey L; Bernstein, Jeffrey N.; Hurlbut, Katherine.

In: Archives of Internal Medicine, Vol. 154, No. 2, 24.01.1994, p. 221-224.

Research output: Contribution to journalArticle

@article{9ec893f2ca3b406f80a747979b550274,
title = "A case report with prolonged cholinesterase inhibition and improvement after pralidoxime therapy",
abstract = "AIdicarb is the most potent of the commercially available carbamate pesticides and is an unusual source of acute human poisonings. We present the case of a 43-year-old man exposed to aldicarb who developed severe cholinergic symptoms and progressive weakness requiring intubation for 5 days. Both his red blood cell cholinesterase and plasma pseudocholinesterase levels were depressed for a minimum of 44 hours. He demonstrated neuromuscular improvement concurrent with pralidoxime administration. The pertinent medical literature on aldicarb poisoning is reviewed.",
author = "Burgess, {Jefferey L} and Bernstein, {Jeffrey N.} and Katherine Hurlbut",
year = "1994",
month = "1",
day = "24",
language = "English (US)",
volume = "154",
pages = "221--224",
journal = "JAMA Internal Medicine",
issn = "2168-6106",
publisher = "American Medical Association",
number = "2",

}

TY - JOUR

T1 - A case report with prolonged cholinesterase inhibition and improvement after pralidoxime therapy

AU - Burgess, Jefferey L

AU - Bernstein, Jeffrey N.

AU - Hurlbut, Katherine

PY - 1994/1/24

Y1 - 1994/1/24

N2 - AIdicarb is the most potent of the commercially available carbamate pesticides and is an unusual source of acute human poisonings. We present the case of a 43-year-old man exposed to aldicarb who developed severe cholinergic symptoms and progressive weakness requiring intubation for 5 days. Both his red blood cell cholinesterase and plasma pseudocholinesterase levels were depressed for a minimum of 44 hours. He demonstrated neuromuscular improvement concurrent with pralidoxime administration. The pertinent medical literature on aldicarb poisoning is reviewed.

AB - AIdicarb is the most potent of the commercially available carbamate pesticides and is an unusual source of acute human poisonings. We present the case of a 43-year-old man exposed to aldicarb who developed severe cholinergic symptoms and progressive weakness requiring intubation for 5 days. Both his red blood cell cholinesterase and plasma pseudocholinesterase levels were depressed for a minimum of 44 hours. He demonstrated neuromuscular improvement concurrent with pralidoxime administration. The pertinent medical literature on aldicarb poisoning is reviewed.

UR - http://www.scopus.com/inward/record.url?scp=0027953511&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027953511&partnerID=8YFLogxK

M3 - Article

VL - 154

SP - 221

EP - 224

JO - JAMA Internal Medicine

JF - JAMA Internal Medicine

SN - 2168-6106

IS - 2

ER -